BRAF and neoplasm: CDKN2A depletion is recurrently acquired by 7%-28% progressed melanoma patients on treatment with BRAFi or BRAF/MEKi 80, 85, which facilitates tumor cells to overcome cell cycle arrest and subsequent apoptosis.